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Abstract: In controlled group sequential trials, we consider the ratio of normal means
as the effect measure of interest and derive group sequential nested confidence intervals
on this parameter. In an interim analysis, the sample sizes of the following stages can
be determined in a completely adaptive way using the unblinded data from all previously
performed stages. Despite the data-dependent adaptation, the nested confidence intervals
always keep the predefined confidence coefficient.
Using nested confidence intervals, we make test decisions either in noninferiority or
in superiority trials. However, in an interim analysis, we can change the planning from
showing noninferiority to showing superiority or vice versa without affecting the predefined
confidence coefficient of the nested intervals.
A real data example is worked out in detail and the change in the planning from
showing superiority to showing noninferiority is shown during the ongoing trial.
Keywords: Ratio of means; Adaptive sample size planning; Switching between noninfe-
riority and superiority; Group sequential clinical trials
1 Introduction
In clinical trials, the difference or the ratio of normal means are the common effect mea-
sures for showing at least noninferiority of a new treatment compared to a standard
(active) treatment. Provided the standard treatment is well known and stable in different
populations, the suitable effect measure is the difference of means. Otherwise, the scale
invariant ratio of means is the preferred effect measure.
In analyzing the trials, the confidence interval approach is of particular attractiveness.
Group sequential confidence intervals for the difference of means are known as repeated
confidence intervals, see Jennison and Turnbull (2000) and references cited therein, Har-
tung and Knapp (2006).
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A well-known confidence interval for the ratio of normal means was derived by Fieller
(1940). Fieller parameterized a F -statistic, where the ratio of the means, say λ, is the
parameter of interest. The boundaries of the confidence interval are found by equating
the F -statistic to quantiles of an appropriate F -distribution and solving for the unknown
parameter. The boundaries are given by solving a quadratic equation, see also Finney
(1964). In spite of its practical importance, the ratio of means does not seem to be
considered in group sequential trials until now, neither for testing noninferiority nor for
deriving confidence intervals.
In this paper, we will extend the proceeding of Fieller (1940) to group sequential
trials that are designed for a fixed number, say K, of independent stages, where the
ratio of normal means is the parameter of interest. We consider pivotal t-statistics in
each stage involving the unknown parameter λ and combine the pivotal statistics using
the inverse normal method from meta-analysis, see for instance Hartung, Knapp, and
Sinha (2008). As with Fieller’s confidence interval, the multi-stage confidence intervals
are defined implicitly and, for obtaining the boundaries, nonlinear equations have to be
solved. However, the solutions are always unique.
In each stage k, 1 ≤ k ≤ K, a confidence interval on λ will be computed using the data
of all previous stages. The consecutive intersection of these individual confidence intervals
leads to a sequence of intervals that are nested. This property is of particular interest
in the confidence interval approach to the analysis of noninferiority trials, see Bauer and
Kieser (1996) and, for instance, the clinical trial guideline EMEA (2000). Practically this
means that the position of the confidence interval determines the kind of result of the
study, independently of the question, whether the study has been originally planned as
a noninferiority or as a superiority trial. The consequence of the proposed confidence
interval intersection-approach is that, if we gain significance for noninferiority at an early
stage of the trial, we will not take a risk to lose this significance in case we decide to
continue the trial for an attempt of showing superiority.
In group sequential trials, interim analyses are based on the unblinded data. Since
stochastically independent and uniformly distributed p-values will be combined for con-
structing the confidence intervals, the information from the interim analyses of the pre-
vious stages may be used for an adaptive sample size calculation of the following stage,
see Brannath, Posch, and Bauer (2002), Hartung (2006). We will provide concrete rules
for updating sample sizes during the course of the group sequential trial.
The outline of the present paper is as follows: In Section 2.1, one-sided group sequential
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confidence intervals for the ratio of normal means are derived. Moreover, we consider
the change from showing noninferiority to showing superiority during the course of the
group sequential trial. In Section 2.2, two-sided confidence intervals and a test on the
homogeneity of the ratios of the mean treatment effects underlying the K independent
stages are presented. A group sequential confidence interval on the variance parameter is
given in Section 3. General adaptive sample size planning is considered in Section 4. In
Section 5, a real data example is presented that uses an adaptive design of O’Brien and
Fleming (1979) type. In the example, the switching from showing superiority to showing
noninferiority is shown during the ongoing trial. Moreover, after the first interim analysis,
the design was changed from a three-stage into a two-stage design and we will show how
to make full use of the type I error rate despite the shortening of the originally planned
trial, that is, we will not lose any power. Some final remarks are given in Section 6, where
especially point estimation of the ratio λ is briefly addressed.
2 Group Sequential Confidence Intervals for the Ra-
tio of Normal Means
Let XE and XC be stochastically independent normally distributed random variables with
mean µE ≥ 0 in an experimental group E, mean µC > 0 in an active control group C,
and common variance σ2 > 0, succinctly, XE ∼ N (µE, σ2) and XC ∼ N (µC , σ2). The
parameter of interest is the ratio of the means, say λ, that is,
λ =
µE
µC
, 0 ≤ λ <∞, µE ≥ 0, µC > 0.
Let ∆0, with 0 ≤ ∆0 < 1, be a noninferiority margin, we are interested in hypothesis
testing of
H0,∆ : λ = 1−∆ versus H1,∆ : λ > 1−∆, 0 ≤ ∆ ≤ ∆0, (1)
at a predefined level α, 0 < α < 1/2. The alternative hypothesis H1,∆ stands for
(∆-)noninferiority, 0 < ∆ ≤ ∆0, and means superiority of the experimental group E
with regard to the control group C for ∆ = 0.
We consider a comparative study which is carried out consecutively in a number of
independent stages, say K. In the i-th stage, i = 1, . . . , K, let be X¯Ei ≥ 0 and X¯Ci > 0
the sample means of nEi ≥ 2 and nCi ≥ 2 responses in the respective treatment groups.
The variance parameter σ2 is estimated in the i-th stage by the pooled sample variance
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S2i , which is stochastically independent of the means and follows a scaled χ
2-distribution
with nEi + nCi − 2 degrees of freedom, that is
(nEi + nCi − 2)
S2i
σ2
∼ χ2nEi+nCi−2. (2)
2.1 Nested One-Sided Confidence Intervals
For the i-th stage, i = 1, . . . , K, let us introduce the pivotal statistic
X¯i(λ) = X¯Ei − λ X¯Ci ∼ N
(
0,
( 1
nEi
+
λ2
nCi
)
σ2
)
, X¯Ei ≥ 0, X¯Ci > 0, (3)
and define the parameterized pivotal t-statistic
Ti(λ) =
X¯Ei − λ X¯Ci
Si
√
1/nEi + λ
2/nCi
∼ tni−2, ni = nEi + nCi . (4)
That is, for the true parameter λ, the pivotal statistic Ti(λ) from (4) follows a central
t-distribution with nEi + nCi − 2 degrees of freedom.
Let Ftν denote the cumulative distribution function of a t-variable with ν degrees of
freedom, then it holds, for the 1− p-value,
Ftni−2(Ti(λ)) ∼ U(0, 1), ni = nEi + nCi , (5)
where U(0, 1) stands for the uniform distribution in the unit interval. Consequently, we
obtain
Φ−1[Ftni−2(Ti(λ))] ∼ N (0, 1), i = 1, . . . , K, (6)
with Φ−1 the inverse of the standard normal cumulative distribution function Φ.
The stages of the trial are assumed to be independent. Consequently, up to the j-th
stage, we define the combining pivotal statistic
Zj(λ) =
j∑
i=1
Φ−1
[
Ftni−2(Ti(λ))
] ∼√j N (0, 1), j = 1, . . . , K. (7)
Let Y1, . . . , YK , in general, be mutually independent N (0, 1)-distributed random vari-
ables. Then, for predefined level α, 0 < α < 1/2, positive critical values cv1, . . . , cvK may
be defined which satisfy the following probability statement,
P
(
j∑
i=1
Yi ≤ cvj for all j = 1, . . . , K
)
= 1− α. (8)
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For fixed number of stages K and overall significance level α, we get an O’Brien and
Fleming (1979) design with constant critical values in (8), say cvj = consOBF (K,α),
and a Pocock (1977) design with monotone increasing critical values given as cvj =√
j consPO(K,α), j = 1, . . . , K, see Hartung (2006).
Note that upper and lower critical values at level 2α for the corresponding symmetric
two-sided tests are usually tabulated in the literature, which, for K ≥ 2, are slightly
closer to zero than the one-sided critical values at level α. But at least for α ≤ 0.05, these
upper and lower two-sided critical values may be used as critical values in one-sided test
problems for most practical applications, see Jennison and Turnbull (2000, p. 192).
Using critical values cvj defined by (8), we get the following probability statements
for the combining pivotal statistic from (7),
Pλ
(
Zj(λ) ≤ cvj for j = 1, . . . , k ≤ K
)≥ 1− α for k < K,= 1− α for k = K. (9)
Definition 1. The group sequential lower confidence sets on the ratio λ are defined as
CIk,L(λ) = {λ˜ ≥ 0 | Zj(λ˜) ≤ cvj for j = 1, . . . , k}, k = 1, . . . , K. (10)
By (9), we can directly state the following lemma:
Lemma 1. The lower confidence sets from Definition 1 are nested, that is,
CIk+1,L(λ) ⊂ CIk,L(λ), k = 1, . . . , K − 1, (11)
and the confidence coefficient of CIk,L(λ) is at least 1− α, and exactly 1− α for k = K.
In order to show that these confidence sets are genuine intervals, we need a further
lemma.
Lemma 2. The statistics Zj(λ), j = 1, . . . , K, from (7) are monotone decreasing in λ,
for 0 ≤ λ <∞.
Proof. At first, we show that the pivotal t-statistics Ti(λ), i = 1, . . . , K, are (strictly)
monotone decreasing in λ for λ ≥ 0.
Suppressing the subscript i and putting Q = (1/nE + λ
2/nC) S
2)1/2, we get the
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derivative
d
dλ
T (λ) =
−X¯C Q− (X¯E − λ X¯C) Q−1 S2 λ / nC
Q2
=
−X¯C Q2 − (X¯E − λ X¯C) S2 λ / nC
Q3
=
−(X¯C / nE + λ X¯E / nC) S2
Q3
< 0 for λ ≥ 0,
(12)
so that T (λ) is monotone decreasing for nonnegative λ. Since the functions Ftν (·) and
Φ−1(·) used in building Zj(λ), see (7), are both (strictly) monotone increasing functions
in their arguments, the function Φ−1(Ftν (T (λ))) is monotone decreasing in λ ≥ 0. Hence
the combined statistic Zj(λ) from (7) is monotone decreasing in λ for λ ≥ 0. 
Moreover, the combining pivotal statistic Zj(λ) is a bounded function with respect to
λ ≥ 0, that is, see (7), for j = 1, . . . , K,
j∑
i=1
Φ−1
[
Ftni−2
(
X¯Ei√
S2i / nEi
)]
= Zj(0) ≥ Zj(λ) > inf
λ>0
Zj(λ)
=
j∑
i=1
Φ−1
[
Ftni−2
(
−X¯Ci√
S2i / nCi
)]
=: Zj(∞).
(13)
Let us define, in the j-th stage, the following individual lower confidence set for λ,
Ij,L(λ) = {λ˜ ≥ 0 | Zj(λ˜) ≤ cvj}, j = 1, . . . , K. (14)
Then, by Lemma 2, the confidence set (14) is a connected lower bounded one-sided con-
fidence interval on λ. This interval can also be described as
Ij,L(λ) = [λL(j),∞), (15)
where λL(j) solves: Zj(λL(j)) = cvj if Zj(0) > cvj, otherwise λL(j) = 0, j = 1, . . . , K.
Note that the solution in (15) is unique and can be easily found iteratively using, for
instance, the bisection method.
Since CIk,L from (10) is the intersection of the individual confidence intervals from
(14) up to stage k, that is,
CIk,L(λ) = I1,L(λ) ∩ . . . ∩ Ik,L(λ), k = 1, . . . , K, (16)
we can summarize the above findings as follows.
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Theorem 1 The lower confidence interval on λ with a confidence coefficient of at least
1− α, 0 < α < 1/2, is given in the k-th stage, k = 1, . . . , K, by
CIk,L(λ) = [λLk,∞) (17)
where λLk = max{λL(1), . . . , λL(k)} with λL(j) from (15), j = 1, . . . , k. For k = K, the
confidence coefficient is exactly 1− α.
Let us now apply these group sequential confidence intervals to the test problem (1) at
level of at most α. At stage k, k = 1, . . . , K, using λLk from (17), we proceed as follows:
if 1−∆ < λLk, then we decide for H1,∆, ∆ ∈ [0,∆0],
if 1−∆0 ≥ λLk, then we stay with H0,∆0 .
If we are satisfied with showing noninferiority, then we will stop the trial after that
stage k∗, when the value 1 −∆0 lies the first time outside the corresponding confidence
interval. Since the confidence intervals CIk,L are nested and provided k
∗ < K, we may
decide to continue the trial without any risk to lose the noninferiority once shown. In
case unexpected favorable estimates of the involved parameters have been observed up to
stage k∗, this may lead to considerations to switch from showing noninferiority to showing
superiority. The trial is then continued by planning with ∆ = 0.
Conversely, originally planned as a superiority trial, a first interim analysis may reveal
that an unexpected high number of subjects would be required for showing superiority.
So, in case of an active control, one may decide to switch from showing superiority to
showing noninferiority, and to reduce the sample size of the rest of the trial by choosing
some ∆ > 0 in the further planning. Note that also in this situation, a noninferiority
bound ∆0 should have been defined at the beginning of the study, see also the discussion
in the clinical trial guideline EMEA (2000).
2.2 Nested Two-Sided Confidence Intervals and Homogeneity
of the Ratios of the Treatment Effects
Let us define in analogy to (10) the upper confidence sets for λ as
CIk,U(λ) = {λ˜ ≥ 0 | −cvj ≤ Zj(λ˜) for j = 1, . . . , k}, k = 1, . . . , K. (18)
Again, the confidence sets are nested, that is, CIk+1,U(λ) ⊂ CIk,U(λ), k = 1, . . . , K − 1,
and each confidence set has a confidence coefficient of at least 1−α and exactly 1−α for
k = K.
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Definition 2. The group sequential two-sided confidence set for λ in stage k, say CIk(λ),
is defined as the intersection of the lower and the upper confidence sets from (10) and
(18), respectively, that is,
CIk(λ) = CIk,L(λ) ∩ CIk,U(λ), k = 1, . . . , K. (19)
Let Ij,U(λ) = {λ˜ ≥ 0 | −cvj ≤ Zj(λ˜)} denote the individual upper confidence set in
the j-th stage. In analogy to (15), we get the following interval representation,
Ij,U(λ) = [0, λU(j)], (20)
where λU(j) uniquely solves: Zj(λU(j)) = −cvj if Zj(∞) < −cvj, otherwise λU(j) = ∞.
So the upper confidence set CIk,U from (18) has the interval representation,
CIk,U(λ) = [0, λUk], k = 1, . . . , K, (21)
where λUk = min{λU(1), . . . , λU(k)} with λU(j) from (20), j = 1, . . . , k.
Summarizing the above considerations, we can formulate the following results.
Theorem 2. The two-sided confidence set CIk(λ) has the interval representation
CIk(λ) = [λLk, λUk], k = 1, . . . , K, (22)
where λLk is from (17) and λUk is from (21). The confidence intervals are nested,
CIk+1(λ) ⊂ CIk(λ), k = 1, . . . , K − 1,
and each confidence interval has a confidence coefficient of at least 1− 2α, 0 < α < 1/2.
Remark 1. Denote Ik = [λL(k), λU(k)], see (15) and (20), the individual two-sided con-
fidence interval in the k-th stage, then CI1 = I1 and CIk = CIk−1 ∩ Ik, k = 2, . . . , K.
Depending on the choice of α, the two-sided confidence interval CIk from (22) may
be empty, that is, it may occur that λUk < λLk. For interpreting such an event, let
us consider the extended model that each stage has an individual parameter, say λi =
µEi/µCi , i = 1, . . . , K. Let b
′ = (b1, . . . , bk) denote the transposed of a vector b in the
nonnegative orthant IRk+ of IR
k, then, by (6) and (8), the k-dimensional confidence region,
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k = 1, . . . , K,
CRk =
{
b ∈ IRk+ | −cvj ≤ Zj(b1, . . . , bj)
:=
j∑
i=1
Φ−1
[
FtnEi+nCi−2
(
X¯Ei − bi X¯Ci√
(1/nEi + b
2
i /nCi) S
2
i
)]
≤ cvj for j = 1, . . . , k
} (23)
covers the parameter vector (λ1, . . . , λk)
′ with the probability of at least 1− 2α, 0 < α <
1/2. Note that CRk is not empty for all α ∈ (0, 1/2), as, for instance, the realized vector
(x¯E1/x¯C1 , . . . , x¯Ek/x¯Ck)
′ always lies within CRk.
When we assume that the parameters λi are really identical, say λi = λ, i = 1, . . . , k,
then the k-dimensional parameter vector (λ, . . . , λ)′k is covered by CRk, or, in other words,
(λ, . . . , λ)′k ∈ CRk with probability of at least 1 − 2α. But this is equivalent to λ ∈ CIk
with probability of at least 1− 2α. Thus, if CIk is empty for a common confidence level
1 − 2α, this will speak against the assumption of an identical ratio of mean treatment
effects over the first k stages. This can formally be stated as a test on homogeneity of the
ratios.
In testing
H0,hom(k) : λ1 = . . . = λk versus H1,hom(k) : λi1 6= λi2 , (24)
for some i1, i2 ∈ {1, . . . , k}, k = 2, . . . , K, the homogeneity hypothesis H0,hom(k) will be
rejected at level of at most 2α, if the confidence interval CIk from (22) is empty. If
H0,hom(k
∗) is rejected, then also H0,hom(k) will be rejected for k∗ ≤ k ≤ K. An alternative
to this homogeneity test does not seem to be known.
Finally, we would like to remark that, in the case K = 1, we can solve (15) and (20)
explicitly, and we get Fieller’s well-known confidence interval for the ratio of means, see
Fieller (1940), Finney (1964).
3 Group Sequential Confidence Intervals on the Vari-
ance Parameter
Let Fχ2ν denote the cumulative distribution function of a χ
2-variate with ν degrees of
freedom. Using the pivotal χ2-statistics from (2), which are monotone decreasing in
σ2 > 0, we obtain, in analogy to (5),
Fχ2ni−2
(
(ni − 2) S
2
i
σ2
)
∼ U(0, 1), ni = nEi + nCi , i = 1, . . . , K,
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leading to the combining pivotal statistics
ZVj (σ
2) =
j∑
i=1
Φ−1
[
Fχ2ni−2
(
(ni − 2) S
2
i
σ2
)]
∼
√
j N (0, 1), j = 1, . . . , K, (25)
which are monotone decreasing in σ2 > 0.
Since the confidence level for the variance parameter is usually chosen lower than for
the outcome measure, let cv1(κ), . . . , cvK(κ) denote critical values that yield the (one-
sided) confidence level 1− κ, 0 < κ < 1/2, in (8).
Let σ2L(j) and σ
2
U(j) be the unique solutions for σ
2 of the equations
ZVj (σ
2) = cvj(κ) and Z
V
j (σ
2) = −cvj(κ), j = 1, . . . , K. (26)
Then, in analogy to (22), we build the confidence intervals for σ2 as
V CIk(σ
2) = [σ2Lk, σ
2
Uk], (27)
where σ2Lk = max{σ2L(1), . . . , σ2L(k)} and σ2Uk = min{σ2U(1), . . . , σ2U(k)}, k = 1, . . . , K.
The confidence intervals on σ2 from (27) are nested, that is, V CIk+1 ⊂ V CIk, k =
1, . . . , K − 1, and the confidence coefficients are at least 1 − 2κ, 0 < κ < 1/2. For small
κ, an empty interval indicates that the assumptions of homogeneous variances over the
stages may be violated.
Since descriptions of the standard deviation are preferable in documentation, we simply
take the square root of the boundaries in V CIk and denote the resulting confidence interval
on σ by V CI
1/2
k .
4 Adaptive Sample Size Planning for the Effect Mea-
sure Ratio of Means
Planning with equal sample sizes in both two groups and suppressing the subscript i, we
set nE = nC = m, ξ = µE − (1 −∆) µC , and X = XE − (1 −∆) XC , for a fixed value
∆ ∈ [0,∆0]. Then we have with σ(X)2 = [1 + (1−∆)2] σ2, see (3),
X ∼ N (ξ, σ(X)2) and X¯ ∼ N (ξ, 1
m
σ(X)2
)
.
Let us first consider the test of the point hypotheses
H∗0 : ξ = 0 versus H
∗
1 : ξ = ξ
∗ > 0
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using
T0(1−∆) =
√
m
X¯
σ(X)
∼ N (0, 1) under H∗0.
Then, for given level α, 0 < α < 1, and power 1− β, 0 < β < 1, the required sample size
m is given as (one-sample formula)
m =
[
max{0,Φ−1(1− α) + Φ−1(1− β)}]2[
ξ∗/σ(X)
]2 . (28)
Let s20 > 0 be a prior value for σ
2 and ξ∗ = µE0− (1−∆)µC0 > 0 be a parameter value
in the alternative H1,∆, see (1), then the expected effect size ξ
∗/σ(X) in (28) is given as
A0(∆) :=
µE0 − (1−∆)µC0
s0
√
1 + (1−∆)2 . (29)
Note that, for ease of presentation, we will use the normal sample size spending function
from (28) in the following though we use t-statistics in fact. In practice, by correcting
the sample size m with the variance of a tm−1-variate, that is, by replacing m through
m(m−1)/(m−3), m ≥ 4, the nearly exact sample size can be determined in a one-sample
setting.
We introduce now two steering parameters for each stage j, say vj and wj, in order
to cover a wide range of reasonable updating possibilities. We plan with equal sample
sizes for both groups at each stage. After stage j, let be Aj(∆) > 0 a value for the effect
size ξ∗/σ(X), where Aj(∆) is defined below. Then, conditioned on Aj(∆) > 0, a power
of 1 − β at µE − (1 − ∆) µC = Aj(∆) σ
√
1 + (1−∆)2 in the alternative H1,∆ of (1)
is approximately reached using t-statistics when the total sample size for both groups is
chosen as
fj(α, β,∆) = 2
[
max{0,Φ−1(1− α) + Φ−1(1− β)}]2
Aj(∆)2
, j = 0, 1, . . . , K, (30)
with
Aj(∆) = wj
j∑
i=1
ni∑j
h=1 nh
x¯Ei − (1−∆) x¯Ci
si
√
1 + (1−∆)2
+ (1− wj) µE0 − (1−∆)µC0
[vj s(j) + (1− vj) s0]
√
1 + (1−∆)2 > 0,
s(j) =
(
j∑
i=1
ni − 2∑j
h=1 nh − 2j
s2i
)1/2
, ni = nEi + nCi , 0 ≤ ∆ < 1,
0 ≤ wj ≤ 1, w0 = 0, and 0 ≤ vj ≤ 1, v0 = 0,
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where x¯Ei , x¯Ci , and s
2
i are the realizations of X¯Ei , X¯Ci , and S
2
i up to stage j, i = 1, . . . , j.
Choosing wj = 0 and vj = 0 in (30), we obtain a purely prior information based
sample size plan. The choice of wj = 0 and vj > 0 leads to adaptive plans that only
use updated variances, where s(j)2 denotes the pooled estimator of σ2 up to stage j. For
wj = 1, the term Aj(∆) is a version of the meta-analytical combination of effect sizes.
Putting wj = 0, when the first sample based estimate in Aj(∆) is below the second one,
gives priority to the second term as a lower bound. The reverse choice of wj covers a
situation considered in a two-stage trial by Liu and Chi (2001), and Proschan, Liu, and
Hunsberger (2003), who also discussed the role of the effect size in updating sample sizes.
Recall now from (8) that it holds{
h∑
i=1
Yi ≤ cvh for h = 1, . . . , j − 1 and
j−1∑
i=1
Yi +
√
K − (j − 1) Yj ≤ cvK
}
⊃
{
h∑
i=1
Yi ≤ cvh for all h = 1, . . . , K
}
.
(31)
In the group sequential trial, the hypothesis H0,∆ will be rejected if Zj(1−∆) > cvj, see
(7) and (9). Then, by (31), if we decide after stage j − 1 to omit the interim analyses j
up to K− 1, we can assign the remaining weight √K − j + 1 to the next final study part
and build the final test statistic as
Zj,K(1−∆) = Zj−1(1−∆) +
√
K − j + 1 Φ−1[Ftnj−2(Tj(1−∆))]. (32)
Note that it holds Zj,K(1 − ∆) ∼
√
K N (0, 1) under H0,∆, j = 1, . . . , K, and define
Z0(1−∆) = 0. The test statistic Zj,K(1−∆) has to be compared with the K-th critical
value cvK in testing H0,∆.
The p-value of testing H0,∆ is given at stage i by use of Ti(1−∆) as
pi = pi(∆) = 1− Ftni−2(Ti(1−∆)), i = 1, . . . , K. (33)
Provided that a significant result has not been reached in the first j − 1 stages, that is,
Zi(1−∆) ≤ cvi for i = 1, . . . , j − 1, and in the next study part we want to attain cvK by
use of the final test statistic
Zˆj,K(1−∆) = Zj−1(1−∆) +
√
K − j + 1 Φ−1(1− pˆj,K(∆)),
then the projected p-value pˆj,K(∆) of the next study part should be
pˆj,K(∆) = 1− Φ
[
(cvK − Zj−1(1−∆))/
√
K − j + 1
]
. (34)
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To detect a deviation of the null-hypothesis H0,∆ in direction of H1,∆ at
µE − (1 −∆)µC = Aj−1(∆) σ
√
1 + (1−∆2) > 0 with the (conditional) power (1 − β),
the sample size for the next final study stage must be chosen using (30) as
Mj = Mj(∆) = fj−1 (pˆj,K(∆), β,∆) . (35)
If we do no want to finish the trial in this way and have in mind the originally planned
K − (j − 1) further stages, we suggest choosing the sample size of stage j proportionally
as
nj = nj(∆) =
Mj(∆)
K − j + 1 , nEj = nCj ≈ nj/2, j = 1, . . . , K. (36)
Recall that the sample sizes should be at least 2 in each stage and group.
For j = 1 and pˆ1,K = 1 − Φ
(
cvK/
√
K
)
, we obtain the starting sample size of the
group sequential trial as
n1 = M1/K, (37)
where
M1 = 2
(
cvK√
K
+ Φ−1(1− β)
)2
/A0(∆)
2,
with A0(∆) > 0 from (29) and 0 < β < 1/2. Since A0(1−∆) has the same structure as
Ti(∆), A0(∆) is increasing in ∆, see Lemma 2, and n1 is maximum for ∆ = 0, that is,
the sample size is maximum for the superiority trial as it should be.
Starting with n1 observations from (37) in the first stage and applying the proceeding
presented above, we reach the full power 1− β, conditioned on
µE − (1−∆)µC = AK−1(∆) σ
√
1 + (1−∆)2 > 0,
latest in stage j = K, if the trial does not stop earlier because of shown significance.
Note that, see (5) and (33), we may formally define the p-values as suiting to the
null-hypothesis that λ is the true parameter, see Cox and Hinkley (1974, p. 221). So
we may apply the general result that, under the null-hypothesis, p-values preserve their
distribution and independence (for continuous null-distributions) when sample sizes are
adaptively chosen in a consecutive way, see Brannath, Posch, and Bauer (2002). All the
presented procedures are based on such p-values. Consequently, the statements of Section
2 and 3 remain valid when sample sizes are adaptively chosen as demonstrated in this
section, see also Hartung (2006).
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Table 1: Data and (≥ 0.95)-confidence intervals on λ and σ using a noninferiority margin
∆0 = 10%, and prior guess in stage 0.
Stage Sample size Data (in `) on Confidence intervals on
i ni µE µC σ λ = µE/µC σ
0 - 2.75 2.50 0.75 [1−∆0 = 0.90]
1 128 2.67 2.55 0.81 [0.8604, 1.2765] [0.6621, 1.0287]
2/3 56 2.70 2.56 0.87 [0.9483, 1.1646] [0.7547, 0.9482]
5 A Real Data Example
Let us consider a clinical trial one of the authors was concerned with as a statistical
advisor. Two different inhalers, a new drug (E) and a standard drug (C), for treating
patients with asthma bronchiale are compared with respect to a lung function parameter
named FEV1: forced expiratory volume in 1 second, measured in liter (`). The ratio of
means is the common outcome measure and an often used noninferiority margin is ∆0 =
0.10 in this field of application. The one-sided significance level is chosen as α = 0.025
and the power should be 1− β = 0.90 at the expected effect size. The sample sizes of the
two treatment groups are equal at each stage and the drugs are equally randomized within
blocks of size 8. The involved investigators were optimistic so that the trial started with
an attempt to show superiority. That means ∆ = 0 in the testing problem (1), which
then is equivalent to testing the difference of the means. So we could use sample size
calculations of usual group sequential trials for the purpose of comparison, for instance,
from Jennison and Turnbull (2000).
Since no early significant results were expected, the decision was made in favor of an
adaptive three-stage design of O’Brien and Fleming (1979) type. Using the combining
statistic (7), we obtain the constant critical values cvj = consOBF (3, 0.025) = 3.471(=
2.004
√
3) for j = 1, 2, 3 in (8), see Jennison and Turnbull (2000, p. 29), Hartung (2006,
p. 533). Planning with ∆ = 0 for showing superiority, we obtain the prior guess A0(0) =
0.2357, see (29), using the prior guesses for the means and the standard deviation from
Table 1.
Using (30), we would need 378 patients in a one-stage fixed sample size test. With
Jennison and Turnbull (2000, p. 30), each stage in a three-stage fixed sample size O’Brien
and Fleming test should have 1.016 × 378/3 ≈ 128 patients for testing H0,0 : µE = µC
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versus H1,0 : µE > µC and σ
2 known. Formula (37) yields the value 388/3 ≈ 130 patients
as starting sample size n1.
We started with n1 = 128 patients because of the randomization scheme using blocks
of size 8. In the first stage, we observed x¯E1 = 2.67, x¯C1 = 2.55, and s1 = 0.81, see Table
1, that led to Z1(1) = 0.8352, see (7). Equating Z1(λ) to the critical values 3.471 and to
−3.471 and solving for λ yields the first confidence interval on the ratio λ = µE/µC as
CI1 = [0.8604, 1.2765].
It turned out that the prior guesses of the parameters were too optimistic with respect
to the new drug. Therefore, we used only the observed values from the first stage in the
further planning, especially as these values were based on a relatively large number of
patients. Consequently, the weight wj in the sample size spending function (30) was set
to wj = 1 for the next stage leading to A1(0) = 0.1048. The projected p-value according
to (34) is
pˆ2(0) = 1− Φ
(
[3.471− 0.835]/
√
2
)
= 0.0312,
leading to n2(0) ≈ 902 = 1804/2 patients for the next stage for showing superiority using
(36). Since the interest in showing superiority came from a marketing point of view, the
easy decision was made to continue the trial with showing noninferiority being sufficient
for regulatory concerns.
Consequently, we used ∆ = ∆0 = 0.10 in the further planning. By (7), we compute
Z1(0.90) = 2.7075 and, by (34), the projected p-value
pˆ2(0.10) = 1− Φ([3.471− 2.7075]/
√
2) = 0.2946.
In the sample size spending function (30), we obtain now A1(0.10) = 0.3441 with w1 = 1.
So, formula (35) yields M2(0.10) ≈ 56 patients for the total sample size of the two
remaining planned stages leading to 32 patients in the second stage because of the block
size of 8. Therefore, it was decided to save the effort with an additional interim analysis
and to omit the originally planned second one. In the final study part, say stage 2/3, the
sample size is n2/3 = 56.
If we would use now the combining statistic (7), we could lose potential power of the
test since we would not make full use of the predefined level α. However, based on the
considerations in Section 4, we can use the combining statistic
Z2,3(λ) = Z1(λ) +
√
2 Φ−1
[
Ftn2/3−2(T2(λ))
]
in the final analysis, see (32). The final test statistic has then to be compared with the
critical value cv3.
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In the final stage 2/3, we observed x¯E2 = 2.70, x¯C2 = 2.56, and s2 = 0.87, see Table 1.
Equating Z2,3(λ) to 3.471 and to −3.471 and solving for λ yielded the second confidence
interval on the ratio λ as CI2/3 = [0.9483, 1.1646], which lies clearly above 0.90.
Further we calculated the final test value,
Z2,3(0.90) = 2.7075 +
√
2× 1.7564 = 5.1914 > 3.471,
which confirms significant noninferiority of the new drug with regard to the standard
drug.
For the confidence intervals on the variance parameter, we chose the same level κ =
0.025, see Section 3, so that we can use the same critical values as above. In the first
stage, we had to equate ZV1 (σ
2) = Φ−1
[
Fχ2126 (126× 0.812/σ2)
]
to 3.471 and to −3.471
and solving for σ2 yielded the first confidence interval on σ2 as VCI1(σ
2) = [0.4384, 1.0582].
In the final stage, we use, in analogy to the considerations above, the combining statis-
tic ZV2,3(σ
2) = ZV1 (σ
2) +
√
2 Φ−1
[
Fχ254 (54× 0.872/σ2)
]
. Equating ZV2,3(σ
2) to 3.471 and
to −3.471 and solving for σ2 yielded the second confidence interval on σ2 as VCI2/3(σ2) =
[0.5696, 0.8991]. Taking the square root of the σ2-boundaries, we get the confidence in-
tervals on σ as presented in Table 1.
6 Final Remarks
In this paper, we defined a two-sided confidence interval CIk on the ratio of normal means
by intersecting the lower and upper one-sided confidence intervals CIk,L and CIk,U on this
parameter with confidence coefficients of 1 − α, respectively. The confidence coefficient
of the two-sided interval CIk is always at least 1 − 2α. If we use the critical values of
the correspondent two-sided test at level 2α, we will get a two-sided confidence interval,
say CI0k, that is slightly narrower than CIk for K ≥ 2, but has a confidence coefficient
of at least 1 − 2α as well. Moreover, the final interval CI0K has a confidence coefficient
of exactly 1− 2α. However, using the lower boundary of CI0k for the test decision in the
test problem (1) as given at the end of Section 2.1, the test level α cannot be guaranteed.
However, no severe differences between both two-sided intervals and test decisions are
expected for practical applications, because, at least for α ≤ 0.05, the involved critical
values are nearly identical, see Jennison and Turnbull (2000, p. 192).
In Section 2.2, we presented the two-sided confidence intervals as CIk = CIk−1 ∩ Ik,
see Remark 1, where Ik results from the boundaries in stage k alone and, thus, is always
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nonempty. Since Ik has also a confidence coefficient of at least 1 − 2α, we could prefer
Ik to CIk, see, for instance, Jennison and Turnbull (2000, p. 192) in their corresponding
settings. But, suppose that up to stage k − 1 the intersections CI`, ` = 1, . . . , k − 1, are
nonempty and CIk is empty for a common level α. That means, the nonempty interval Ik
lies completely outside the nonempty interval CIk−1. Therefore, up to an error rate of 2α,
see (24), we may consider that the ratios of the underlying mean treatment effects are no
longer homogeneous in all the stages. So, with regard to statistical concerns, results from
this stage k should not influence conclusions, or non-conclusions, from the previous stages.
Consequently, preferring Ik to CIk does not provide a real advantage. Nevertheless, one
may try to find an explanation for the revealed treatment behavior. Recall that under the
model assumption of an identical ratio µE/µC in all the stages of the trial, the probability
obtaining an empty interval CIk is bounded by 2α.
Moreover, let us consider the testing problem in a group sequential trial. In a supe-
riority test, the null-hypothesis H0,0 is rejected at level α in favor of H1,0 if we observe
Zk∗(1) > cvk∗ in at least one stage k
∗ ∈ {1, . . . , K} or, equivalently, the lower bound of
Ik∗ lies above 0. Suppose k
∗ < K and the study is continued to obtain more data, for
instance, for safety reasons in clinical trials. Then, in all further stages k > k∗, we may ob-
serve Zk(1) ≤ cvk or that Ik covers 0 without contradicting the already shown superiority.
This fact is able to induce misunderstandings in practical applications caused by a lack
of knowledge of the theoretical background. The same problem may arise when, after a
shown significant noninferiority, the trial is continued for an attempt to show superiority.
Such possible misunderstandings are avoided by using CIk instead of Ik as proposed in
the testing procedure, see Section 2.1. The automatically implied homogeneity test (24)
would react if quite different results would have been observed in later stages.
Finally, let us briefly address point estimation of the parameters λ and σ2. The
combined statistic Zj(λ) from (7) is a N (0, j)-distributed random variable with mode
and median 0. A maximum likelihood (ML) estimator λˆML(j) of the ratio λ = µE/µC
at stage j is given as the solution of Zj(λˆML(j)) = 0. The global p-value at stage j is
pG(j) = 1−Φ
(
Zj(λ)/
√
j
)
, and solving the equation for pG(j) = 1/2 yields λˆML(j) as the
solution. Note, that Zj(λ) is monotone in λ. Consequently, λˆML(j) is a median unbiased
estimator, see Cox and Hinkley (1974, p. 273).
For the variance parameter σ2, we use the combining statistic ZVj (σ
2) from (25). The
ML-estimator σˆ2ML(j) of σ
2 at stage j is given as the solution of ZVj (σˆ
2
ML(j)) = 0. By the
same considerations as above, σˆ2ML(j) is a median unbiased estimator.
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